Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is monitoring the outstanding progress of the 3rd Self-Medicated Cannabis Patient with Clear Continued Improvement. This self-medicating patient has what his doctors describe as the worst case of squamous cell carcinoma the had ever seen. This patient’s tumors, while resistant to conventional treatment, continues to make obvious improvement with the use of cannabis extracts.
Medical Cannabis News & Information
DENVER--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) critical ailment formulations, is excited to announce the appointment of world renowned Cannabis Cultivator Bret Bogue as Director of Horticulture for the company. Mr. Bogue is a valuable addition to the company, with decades of experience growing cannabis for medical purposes.
ANNAPOLIS – A pair of bills were introduced today in the Maryland House and Senate that would allow patients with certain qualifying conditions to use medical marijuana with doctors’ recommendations. The bills, HB 1024 and HB 1148, are based on the recommendations of a study panel created by the legislature in 2011 and were introduced in the House by Del. Dan Morhaim.
DENVER--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to present the newest set of photographs showing evidence that the cancer cells appear to have been killed over the course of treatment from the 2nd self-administering cancer patient suffering from squamous cell carcinoma on her arm.
Sativex® has received regulatory approval in Austria as a treatment of spasticity due to Multiple Sclerosis (MS). The launch of Sativex® in Austria is expected to take place during 2012 following completion of the national pricing and reimbursement process. Sativex® will be marketed in Austria by GW's marketing partner, Almirall S.A.